Literature DB >> 22654467

Vitamin d: popular cardiovascular supplement but benefit must be evaluated.

Thomas F Whayne1.   

Abstract

Vitamin D deficiency is prevalent in the United States. Understanding any relationship between this deficiency and cardiovascular disease is essential. Vitamin D, as used, refers to both D(2) and D(3); both are present in over-the-counter supplements, whereas D(2) is the prescription product in the United States. In the liver, both D(2) and D(3) are converted to 25-hydroxyvitamin D, the major circulating metabolite that is measured to assess activity. The actual active form at a cellular level is 1,25-dihydroxyvitamin D; however, it does not correlate well with overall activity. Estimated vitamin D deficiency is, at times, more than 50%. Despite absence of placebo-controlled randomized trials, much information associates vitamin D deficiency with cardiovascular risk and supports benefit from vitamin D supplementation. There are also reports that explain how this benefit from vitamin D may occur. Vitamin D appears to cause only minimal changes in low- and high-density lipoprotein levels. Therefore, any cardiovascular benefit that may exist from vitamin D probably has an explanation other than an effect on levels of these lipoproteins. There is more association of vitamin D deficiency with metabolic syndrome components such as an increase in blood pressure, elevated plasma triglycerides, and impaired insulin metabolism. Possible documentation of cardiovascular benefit from vitamin D includes some evidence for endothelial stabilization and decreased inflammation in arteries. If the clinician decides that recommendation of vitamin D supplementation is warranted, it is reassuring that toxicity is rare. Furthermore, this toxicity involves doses exceeding those of most clinical trials and mainly has involved hypercalcemia. Vitamin D supplementation is easy and can be taken as a dose of 2000 IU daily on an indefinite basis. In 1997, the Food and Nutrition Board of the U.S. Institute of Medicine considered this the safe tolerable upper limit, but this is not based on current evidence. Some practitioners, especially endocrinologists, recommend vitamin D at a dose of 50,000 IU per week for 8 weeks, repeated if necessary to achieve a normal level of vitamin D. It appears appropriate to assess low vitamin D as a possible cardiovascular risk factor, but potential benefit of supplementation must be weighed against the current absence of definitive outcomes studies.

Entities:  

Keywords:  Cardiovascular risk; coronary heart disease; low-density lipoproteins; peripheral vascular disease; vitamin D

Year:  2011        PMID: 22654467      PMCID: PMC3331634          DOI: 10.1055/s-0031-1279679

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  44 in total

1.  Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study.

Authors:  R Scragg; R Jackson; I M Holdaway; T Lim; R Beaglehole
Journal:  Int J Epidemiol       Date:  1990-09       Impact factor: 7.196

Review 2.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

Review 3.  Overview of general physiologic features and functions of vitamin D.

Authors:  Hector F DeLuca
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

Review 4.  Systematic review: Vitamin D and cardiometabolic outcomes.

Authors:  Anastassios G Pittas; Mei Chung; Thomas Trikalinos; Joanna Mitri; Michael Brendel; Kamal Patel; Alice H Lichtenstein; Joseph Lau; Ethan M Balk
Journal:  Ann Intern Med       Date:  2010-03-02       Impact factor: 25.391

Review 5.  Environmental factors that influence the cutaneous production of vitamin D.

Authors:  M F Holick
Journal:  Am J Clin Nutr       Date:  1995-03       Impact factor: 7.045

6.  Relationship between peripheral arterial disease and metabolic syndrome.

Authors:  Milos Maksimovic; Hristina Vlajinac; Djordje Radak; Jelena Marinkovic; Jagoda Jorga
Journal:  Angiology       Date:  2009-01-14       Impact factor: 3.619

Review 7.  Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?

Authors:  John H Lee; James H O'Keefe; David Bell; Donald D Hensrud; Michael F Holick
Journal:  J Am Coll Cardiol       Date:  2008-12-09       Impact factor: 24.094

8.  Vitamin D production after UVB exposure depends on baseline vitamin D and total cholesterol but not on skin pigmentation.

Authors:  Morten K B Bogh; Anne V Schmedes; Peter A Philipsen; Elisabeth Thieden; Hans C Wulf
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

Review 9.  Vitamin D and cardiovascular disease.

Authors:  Carrie W Nemerovski; Michael P Dorsch; Robert U Simpson; Henry G Bone; Keith D Aaronson; Barry E Bleske
Journal:  Pharmacotherapy       Date:  2009-06       Impact factor: 4.705

10.  Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004.

Authors:  Adit A Ginde; Mark C Liu; Carlos A Camargo
Journal:  Arch Intern Med       Date:  2009-03-23
View more
  4 in total

1.  Atherosclerosis: current status of prevention and treatment.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2011-12

Review 2.  Epigenetics in the development, modification, and prevention of cardiovascular disease.

Authors:  Thomas F Whayne
Journal:  Mol Biol Rep       Date:  2014-09-10       Impact factor: 2.316

Review 3.  Inflammation and vitamin D: the infection connection.

Authors:  Meg Mangin; Rebecca Sinha; Kelly Fincher
Journal:  Inflamm Res       Date:  2014-07-22       Impact factor: 4.575

4.  Association of Vitamin D Deficiency and Degree of Coronary Artery Disease in Cardiac Patients with Type 2 Diabetes.

Authors:  Ewelina A Dziedzic; Jakub S Gąsior; Mariusz Pawłowski; Marek Dąbrowski
Journal:  J Diabetes Res       Date:  2017-11-02       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.